Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Canada (10 Jul 2026), |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Bone Diseases, Metabolic | Canada | 10 Jul 2026 | |
| Bone metastases | Canada | 10 Jul 2026 | |
| Fractures, Bone | Canada | 10 Jul 2026 | |
| Giant Cell Tumor of Bone | Canada | 10 Jul 2026 | |
| Glucocorticoid-induced osteoporosis | Canada | 10 Jul 2026 | |
| Humoral Hypercalcemia of Malignancy | Canada | 10 Jul 2026 | |
| Multiple Myeloma | Canada | 10 Jul 2026 | |
| Osteoporosis | Canada | 10 Jul 2026 | |
| Osteoporosis, Postmenopausal | Canada | 10 Jul 2026 |






